MannKind has patented a method for treating type 2 diabetes using a combination of ultrarapid acting insulin and insulin glargine. The treatment is aimed at improving glycemic control in patients with well-controlled fasting blood glucose but poorly controlled post-prandial glucose, while also avoiding weight gain. GlobalData’s report on MannKind gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MannKind, Smart inhalers was a key innovation area identified from patents. MannKind's grant share as of May 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of diabetes type 2 with ultrarapid acting insulin
A recently granted patent (Publication Number: US11998591B2) discloses a method for treating type 2 diabetes in patients with well or moderately controlled fasting blood glucose but poorly controlled post-prandial glucose, who are also in need of avoiding weight gain. The method involves combining metformin treatment with the administration of an ultrarapid acting insulin (URAI) preparation during meals, resulting in improved glycemic control and reduced weight gain compared to metformin treatment alone. The patients selected for this treatment have an HbA1c level less than or equal to 8.4% and are not currently being treated with basal insulin.
Furthermore, the patent claims include the administration of a GLP-1 agonist in addition to the URAI preparation for enhanced treatment efficacy. The URAI preparation can be in the form of a dry powder, specifically containing a fumaryl diketopiperazine (FDKP) associated with insulin. In cases where patients are already being treated with a suppressor of hepatic glucose output and an insulin secretagogue, the method involves discontinuing the insulin secretagogue and introducing the URAI preparation for better weight management outcomes. The URAI preparation can be administered by inhalation into the lungs, offering a non-invasive alternative to injection methods commonly used for insulin delivery.
To know more about GlobalData’s detailed insights on MannKind, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
